Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial

AIM: To compare the benefits of iGlarLixi, a fixed‐ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with insulin glargine (iGlar) for reducing residual hyperglycaemia (defined as HbA1c ≥ 7% despite fasting plasma glucose [FPG] < 130 mg/dL) in Japanese people with type...

Descripción completa

Detalles Bibliográficos
Autores principales: Iizuka, Katsumi, Baxter, Mike, Watanabe, Daisuke, Yabe, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293167/
https://www.ncbi.nlm.nih.gov/pubmed/34472693
http://dx.doi.org/10.1111/dom.14537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293167/
https://www.ncbi.nlm.nih.gov/pubmed/34472693
http://dx.doi.org/10.1111/dom.14537

Ejemplares similares